Chiome Bioscience Inc.

Equities

4583

JP3205350006

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-25 am EDT			5-day change	1st Jan Change
123 ^JPY	-3.15%		-5.38%	-8.89%

Apr. 01	Chiome Bioscience Cancels License Agreements with ADC Therapeutics	MT
Feb. 13	Chiome Bioscience Inc. Announces Entrustment Agreement with Takeda Pharmaceutical Company Limited	CI

Chiome Bioscience Inc. Reports Earnings Results for the Half Year Ended June 30, 2021

August 13, 2021 at 03:00 am EDT

Chiome Bioscience Inc. announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was JPY 384.932 million compared to JPY 173.278 million a year ago. Operating loss was JPY 415.345 million compared to JPY 735.779 million a year ago. Net loss was JPY 408.737 million compared to JPY 736.036 million a year ago.

Latest news about Chiome Bioscience Inc.

Chiome Bioscience Cancels License Agreements with ADC Therapeutics	Mar. 31	MT
Chiome Bioscience Inc. Announces Entrustment Agreement with Takeda Pharmaceutical Company Limited	Feb. 13	CI
Chiome Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 13	CI
Chiome Bioscience Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 14	CI
Chiome Bioscience Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-09	CI
Chiome Bioscience Inc. announced that it has received ¥13.49304 million in funding from Barclays Bank PLC (Tokyo Branch), Growth Capital, Inc.	23-07-19	CI
Chiome Bioscience Inc. announced that it expects to receive Â¥13.49304 million in funding	23-07-03	CI
Chiome Bioscience Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Chiome Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-14	CI
Chiome Bioscience Inc. Provided Sales Guidance for 2023	23-02-14	CI
Henlius Biotech Terminates License Agreement for Chiome Bioscience's Tumor Drug	23-01-17	MT
Chiome Bioscience Inc. Announces Termination of the License Agreement for Anti-TROP-2 Antibody Development and Commercialization with Shanghai Henlius Biotech, Inc	23-01-17	CI
Chiome Bioscience Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-11-14	CI
Chiome Bioscience Reports Results of Cancer Immunotherapy Joint Research	22-09-09	MT
Chiome Bioscience Signs Research and Option Agreement with Heidelberg Pharma	22-07-14	MT
Heidelberg Pharma Enters Research Collaboration Deal With Japan's Chiome Bioscience	22-07-13	MT
Chiome Bioscience Inc. Announces Conclusion of Target-Specific Research and Option Agreement with Heidelberg Pharma	22-07-13	CI
Japan Index Snaps Three-day Winning Streak on Inflationary Pressures; Kudan Shares Expand 7%	22-07-12	MT
Chiome Bioscience, Rohto Pharmaceutical Sign Deal for Generation of Therapeutic Antibody	22-07-11	MT
Chiome Bioscience Inc. Announces Service Agreement with Option Contract with Rohto Pharmaceutical Co., Ltd	22-07-11	CI
Chiome Bioscience Inc. Announces First Patient in of Cancer Therapeutic Antibody CBA-1535 in A Phase 1 Clinical Trial	22-07-04	CI
Chiome Bioscience Details Progress of Phase I Study of Cancer Drug	22-06-14	MT
Chiome Bioscience Inc. Announces Conclusion of Contract with Additional Institutes and First Dosing of CBA-1205 in the Second Part of Phase 1 Study	22-06-13	CI
Japan Index Trims Gains over Inflationary Pressures; Dena to Take Majority Stake in Mobile ICT Business for $230 Million	22-05-27	MT
Chiome Bioscience, Kidswell Bio to Collaborate on Development of Cancer Antibody	22-05-27	MT

Chart Chiome Bioscience Inc.

Duration

Period

More charts

Company Profile

Chiome Bioscience Inc. is a company mainly engaged in the research and development of antibody drugs, and the provision of development support services. The Company operates in two business segments. The Drug Discovery segment is engaged in the research and development of specific antibodies based on new antigens and mechanisms and licensing to pharmaceutical companies. The Drug Discovery Support segment is engaged in development of lead antibodies for therapeutic drugs in collaborating with pharmaceutical companies in Japan and overseas.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Q1 2025 Earnings Release

More about the company

	1st Jan change	Capi.
CHIOME BIOSCIENCE INC.	-8.89%	45.63M
IQVIA HOLDINGS INC.	+1.61%	43.84B
MODERNA, INC.	+6.04%	41.68B
LONZA GROUP AG	+45.04%	41.25B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+7.41%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-25.43%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.28%	12.29B
MEDPACE HOLDINGS, INC.	+26.58%	12.29B
UNITED THERAPEUTICS CORPORATION	+6.79%	11.15B

Other Biotechnology & Medical Research